Standard BioTools Inc. (LAB)

Market Cap	326.17M -40.8%
Revenue (ttm)	86.26M -3.7%
Net Income	78.21M
EPS	0.20
Shares Out	391.46M
PE Ratio	4.17
Forward PE	41.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	994,427
Open	0.8753
Previous Close	0.8753
Day's Range	0.8200 - 0.8845
52-Week Range	0.7029 - 1.7200
Beta	1.42
Analysts	Buy
Price Target	1.55 (+86.03%)
Earnings Date	Aug 5, 2026

About LAB

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneo...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 10, 2011
• Employees: 389
• Stock Exchange: NASDAQ
• Ticker Symbol: LAB
• Website: https://www.standardbio.com

Financial Performance

In 2025, Standard BioTools's revenue was $85.33 million, a decrease of -6.24% compared to the previous year's $91.01 million. Losses were -$74.90 million, -59.49% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for LAB stock is "Buy." The 12-month stock price target is $1.55, which is an increase of 86.03% from the latest price.

Price Target

$1.55

(86.03% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jul 25, 2026

Data Sources Report a data error